IBRX shares

ImmunityBio (NASDAQ: IBRX) stock surged over 30% in the early trading hours Monday following promising overall survival data release from […]

ImmunityBio (NASDAQ: IBRX) stock soared over 11% in the intraday trading after the FDA approved its bladder cancer therapy. ImmunityBio